SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Qualified Opinion who wrote (20364)6/22/2006 11:09:43 PM
From: Brander  Respond to of 52153
 
What I heard is Pfizer wanted both the short acting and long acting formulations of Indiplon. Since the FDA had some problems with the long acting form, PFE decided it wasn't worth it--with just the short acting formulation, there is no advantage Indiplon offers over several other hypnotics already successfully marketed.